JP2024516037A - Ｓｈｐ２阻害剤とｐｄ－１阻害剤とを含む併用療法 - Google Patents

Ｓｈｐ２阻害剤とｐｄ－１阻害剤とを含む併用療法 Download PDF

Info

Publication number
JP2024516037A
JP2024516037A JP2023567924A JP2023567924A JP2024516037A JP 2024516037 A JP2024516037 A JP 2024516037A JP 2023567924 A JP2023567924 A JP 2023567924A JP 2023567924 A JP2023567924 A JP 2023567924A JP 2024516037 A JP2024516037 A JP 2024516037A
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
compound
patient
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516037A5 (enExample
Inventor
ショジャエイ，ファーボッド
エム． リコノ，ジル
グデノフ，ロバート
ギリングス，ミレイユ
Original Assignee
フヤバイオ インターナショナル，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フヤバイオ インターナショナル，エルエルシー filed Critical フヤバイオ インターナショナル，エルエルシー
Publication of JP2024516037A publication Critical patent/JP2024516037A/ja
Publication of JP2024516037A5 publication Critical patent/JP2024516037A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023567924A 2021-05-05 2022-05-04 Ｓｈｐ２阻害剤とｐｄ－１阻害剤とを含む併用療法 Pending JP2024516037A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163184685P 2021-05-05 2021-05-05
US63/184,685 2021-05-05
US202263320997P 2022-03-17 2022-03-17
US63/320,997 2022-03-17
PCT/US2022/027696 WO2022235817A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and pd-1 inhibitors

Publications (2)

Publication Number Publication Date
JP2024516037A true JP2024516037A (ja) 2024-04-11
JP2024516037A5 JP2024516037A5 (enExample) 2025-05-14

Family

ID=83932910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567924A Pending JP2024516037A (ja) 2021-05-05 2022-05-04 Ｓｈｐ２阻害剤とｐｄ－１阻害剤とを含む併用療法

Country Status (8)

Country Link
US (1) US12097203B2 (enExample)
EP (1) EP4334318A4 (enExample)
JP (1) JP2024516037A (enExample)
AU (1) AU2022271243A1 (enExample)
CA (1) CA3217084A1 (enExample)
IL (1) IL308222A (enExample)
MX (1) MX2023013064A (enExample)
WO (1) WO2022235817A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023012929A (es) * 2021-05-05 2023-11-13 Huyabio Int Llc Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.
CN121013721A (zh) * 2022-11-23 2025-11-25 沪亚生物国际有限公司 包含kras抑制剂和sph2抑制剂的组合疗法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020177653A1 (zh) * 2019-03-04 2020-09-10 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
WO2016203406A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
PT3468972T (pt) * 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN110730678B (zh) 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
WO2019126736A1 (en) 2017-12-21 2019-06-27 New York University Pd-1 related cancer therapy
WO2019152454A1 (en) 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
KR20200143417A (ko) 2018-04-10 2020-12-23 레볼루션 메디슨즈, 인크. Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법
JP2022508651A (ja) * 2018-10-08 2022-01-19 レヴォリューション・メディスンズ，インコーポレイテッド 癌を処置するためのｓｈｐ２阻害剤組成物および方法
EP3923940B1 (en) 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
CN114502165A (zh) 2019-09-23 2022-05-13 苏州浦合医药科技有限公司 Shp2抑制剂及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020177653A1 (zh) * 2019-03-04 2020-09-10 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade", ACTA PHARMACEUTICA SINICA B, vol. 9(2), JPN6024003235, 5 September 2018 (2018-09-05), pages 304 - 315, ISSN: 0005901477 *
CHEN, DAWEI ET AL.: ""SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an An", CANCER IMMUNOLOGY RESEARCH, vol. 8, no. 7, JPN6026028041, 1 July 2020 (2020-07-01), pages 883 - 894, ISSN: 0005901478 *

Also Published As

Publication number Publication date
MX2023013064A (es) 2023-11-15
US12097203B2 (en) 2024-09-24
AU2022271243A1 (en) 2023-11-30
WO2022235817A1 (en) 2022-11-10
IL308222A (en) 2024-01-01
EP4334318A4 (en) 2025-03-05
US20220370457A1 (en) 2022-11-24
CA3217084A1 (en) 2022-11-10
EP4334318A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
US12390469B2 (en) SHP2 inhibitor monotherapy and uses thereof
US20230364096A1 (en) Use of a combination comprising a btk inhibitor for treating cancers
TWI806840B (zh) 使用包含parp抑制劑的組合產品治療癌症
JP6632746B2 (ja) 癌を治療するための１−テトラヒドロピラニルカルボニル−２，３−ジヒドロ−１ｈ−インドール化合物
CN112672744B (zh) 抑制二氢乳清酸脱氢酶的方法和组合物
US20100104567A1 (en) Pharmaceutical composition
CN116472045B (zh) 使用杂芳基联苯基酰胺衍生物治疗癌症的方法
US12097203B2 (en) Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
TW201815417A (zh) Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
CN117677619A (zh) 包含shp2抑制剂和pd-1抑制剂的联合疗法
CN120417936A (zh) B7h3抗体药物缀合物
CN117642398A (zh) 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法
JP2024516998A (ja) Ｓｈｐ２阻害剤とｅｇｆｒチロシンキナーゼ阻害剤とを含む併用療法
HK40108828A (en) Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
HK40108830A (en) Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors
HK40108829A (en) Shp2 inhibitor monotherapy and uses thereof
HK40043086A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
HK40043086B (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260706